Feb22 event *remove after event end

Gain Therapeutics' 2024 R&D update with KOL and Analyst Insight

Register Here >>

subpage banner

Overview

Overview

Corporate Summary

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.

Presentations

Februrary 2024

Corporate Presentation

Q1 2024

Investor Factsheet

Stock
information

Stock Data

GANX

$0 | %

Volume

High

$

Low

$

Market Capital

 

Stock Chart